Health in 2 Point 00, Episode 151| MDLive (not?) IPOing, DTx Platform for Schizophrenia, & more – The Health Care Blog

Health in 2 Point 00, Episode 151| MDLive (not?) IPOing, DTx Platform for Schizophrenia, & more – The Health Care Blog

Health in 2 Point 00

We are forgetting about health tech, and celebrating Chicago-oo! Just kidding, today on Health in 2 Point 00, Jess asks me about Truepill getting a 75M Series C after just closing their B, Sana Benefits getting $20.8M, and Decent getting $10M, both of which are in the space of health benefits & insurance for small business have raised funding, MDLive closing a $50M round for their Virtual Primary Care (but weren’t they going public?), Owl Insights getting $15M from Ascension and Blue Ventures, and Boehringer Ingelheim & Click Therapeutics working on a $500M deal together on a DTx platform for Schizophrenia patients. –Matthew Holt

Subscribe to Health in 2 Point 00’s Channel

Follow @boltyboy & @jessdamassa on Twitter

Subscribe to our channel and tweet us your questions using the hashtag #healthin2point00!

Categories: Health in 2 Point 00, Health Tech, Jessica DaMassa, Matthew Holt
Tagged as: ascention, blue ventures, boehringer ingelheim, Click Therapeutics, decent, Health in 2 Point 00, md live, owl insights, sana benefits, schizophrenia, Truepill

Via Source link